If I read the update correctly, both you and Zman are correct, in the sense that you’re talking about current respiratory devices (“device” sales being impeded at present) and Zman is talking about the marketing/approval costs currently inhibiting Penthrox revenue. Each ‘excuse’ has dampened market sentiment, but for those of us that understand the product life cycle, we’re willing to hold our ‘green chip’ stock based on future sales and agreements in late 2018, 2019, and all going well, 2020(ish) for global domination of Penthrox and Breath-A-Tech.
Ann: Trading Update, page-46
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MVP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
43.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $48.44M | |||
| Open | High | Low | Value | Volume |
| 43.0¢ | 44.0¢ | 43.0¢ | $6.872K | 15.74K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 28506 | 43.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 44.0¢ | 6327 | 1 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| MVP (ASX) Chart |